Citations

Clear

6728 citation(s) found for "Li, Mark".

Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo
Dietz, Allan B. , Souan, Lina , Knutson, Gaylord J., Bulur, Peggy A. , Litzow, Mark R. , Vuk‐Pavlović, Stanimir , Dietz, Allan B

Mayo Clinic

Blood | April 26, 2004 | Volume: 104 | Issue: 4 | Pages: 1094-1099

10.1182/blood-2003-12-4266 | PMID 15100154 Get It

Abstract Imatinib mesylate (STI571, imatinib) inhibited DNA synthesis in primary human T cells stimulated with allogeneic mature dendritic cells or phytohemagglutinin (PHA) but did not induce apoptosis. The values for the concentration that inhibits 50% (IC50) of T-cell proliferation stimulated by dendritic cells and PHA were 3.9 μM and 2.9 μM, respectively, that is, within the concentration range found in patients treated with imatinib mesylate. Interestingly, imatinib mesylate did not inhibit expression of T-cell activation markers CD25 and CD69, although it reduced the levels of activated nuclear factor-κB (NF-κB) and changed phosphorylation or protein levels of Lck, ERK1/2, retinoblastoma protein, and cyclin D3. When T cells were washed free of imatinib mesylate, they proliferated in response to PHA, demonstrating that inhibition is reversible. Treatment with imatinib mesylate led to accumulation of the cells in G0/G1 phase of the cell cycle. The in vitro observations were confirmed in vivo in a murine model of delayed-type hypersensitivity (DTH). In mice treated with imatinib mesylate, DTH was reduced in comparison to sham-injected controls. However, the number of splenic T cells was not reduced showing that, similarly to in vitro observations, imatinib mesylate inhibited T-cell response, but did not cause apoptosis. These findings indicate that long-term administration of high-dose imatinib mesylate might affect immunity.
Differential Trafficking of Transforming Growth Factor-β Receptors and Ligand in Polarized Epithelial Cells
Doré, Jules J.E., Edens, Maryanne, Barnard, J. A., Mitchell, Hugh , Wilkes, Mark C. , Leof, Edward B. , Murphy, Stephen J. , Coffey, Robert J.

Mayo Clinic

Molecular Biology of the Cell | April 12, 2004 | Volume: 15 | Issue: 6 | Pages: 2853-2862

10.1091/mbc.e04-02-0097 | PMID 15075369 Get It

Epithelial cells in vivo form tight cell-cell associations that spatially separate distinct apical and basolateral domains. These domains provide discrete cellular processes essential for proper tissue and organ development. Using confocal imaging and selective plasma membrane domain activation, the type I and type II transforming growth factor-β (TGFβ) receptors were found to be localized specifically at the basolateral surfaces of polarized Madin-Darby canine kidney (MDCK) cells. Receptors concentrated predominantly at the lateral sites of cell-cell contact, adjacent to the gap junctional complex. Cytoplasmic domain truncations for each receptor resulted in the loss of specific lateral domain targeting and dispersion to both the apical and basal domains. Whereas receptors concentrate basolaterally in regions of direct cell-cell contact in nonpolarized MDCK cell monolayers, receptor staining was absent from areas of noncell contact. In contrast to the defined basolateral polarity observed for the TGFβ receptor complex, TGFβ ligand secretion was found to be from the apical surfaces. Confocal imaging of MDCK cells with an antibody to TGFβ1 confirmed a predominant apical localization, with a stark absence at the basal membrane. These findings indicate that cell adhesion regulates the localization of TGFβ receptors in polarized epithelial cultures and that the response to TGFβ is dependent upon the spatial distribution and secretion of TGFβ receptors and ligand, respectively.
Time Dependent Variations in Biomechanical Properties of Cadaveric Fascia, Porcine Dermis, Porcine Small Intestine Submucosa, Polypropylene Mesh and Autologous Fascia in the Rabbit Model: Implications for Sling Surgery
Dora, Chandler , DiMarco, David S., Zobitz, Mark E., Elliott, Daniel S. , Dora, Chandler D

Mayo Clinic

Journal of Urology | April 5, 2004 | Volume: 171 | Issue: 5 | Pages: 1970-1973

10.1097/01.ju.0000121377.61788.ad | PMID 15076323 Get It

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Burritt, Mary F., Therneau, Terry M. , McConnell, Joseph P., Litzow, Mark R. , Gastineau, Dennis A., Tefferi, Ayalew , Inwards, David J. , Micallef, Ivana N. , Ansell, Stephen M. , Porrata, Luis F. , Elliott, Michelle A. , Rajkumar, S. Vincent , Fonseca, Rafaël , Greipp, Philip R., Lust, John A., Zeldenrust, Steven R., Snow, Denise S., Hayman, S. R., McGregor, Christopher G.A. , Jaffe, Allan S. , Gertz, Morie A. , Hogan, William J. , Witzig, Thomas E. , Jaffe, Allan S. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | March 30, 2004 | Volume: 104 | Issue: 6 | Pages: 1881-1887

10.1182/blood-2004-01-0390 | PMID 15044258 Get It

AbstractPrimary systemic amyloidosis (AL) is a fatal plasma cell disorder. Pilot data suggest survival is better in patients undergoing peripheral blood stem cell transplantation (PBSCT), but the selection process makes the apparent benefit suspect. We have reported that circulating cardiac biomarkers are the best predictors of survival outside of the transplantation setting. We now test whether cardiac troponins (cTnT and cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are prognostic in transplant recipients. In 98 patients with AL undergoing PBSCT, serum cardiac biomarkers were measured (cTnT, 98 patients; cTnI, 65 patients; and NT-proBNP, 63 patients). Elevated levels of cTnT, cTnI, and NT-proBNP were present in 14%, 43%, and 48% of patients, respectively. At 20 months median follow-up, median survival has not been reached for patients with values below the thresholds; in patients with values above the thresholds, median survival is 26.1 months, 66.1 months, and 66.1 months, respectively. Our previously reported risk systems incorporating these markers were also prognostic, notably the cTnT/NT-proBNP staging. Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT.
Life-Threatening Reaction to Vancomycin Given for Noninfectious Fever
Johnson, James R. , Burke, Mark S., Mahowald, Maren L., Ytterberg, Steven R.

Mayo Clinic

Annals of Pharmacotherapy | March 11, 2004 | Volume: 33 | Issue: 10 | Pages: 1043-1045

10.1345/aph.18441 | PMID 10534215 Get It

OBJECTIVE: To report a case of vancomycin-induced anaphylaxis (or anaphylactoid reaction) in a patient with a fever of unrecognized noninfectious origin. CASE SUMMARY: An 83-year-old white man, who was a patient of the Veterans Affairs Medical Center, developed a serious anaphylactic (or anaphylactoid) reaction while receiving intravenous vancomycin as empiric therapy for a nosocomial fever of unknown origin. The fever was subsequently proved to have been due to acute polyarticular gout rather than an infection. DISCUSSION: This patient developed respiratory distress and an increased serum troponin concentration, suggestive of a myocardial enzymatic leak as a result of vancomycin therapy. Vancomycin was given before the noninfectious cause of his fever was recognized. CONCLUSIONS: Even with cautious slow infusion, intravenous vancomycin can precipitate life-threatening infusion-related reactions in some patients. Because of this, and to reduce selective pressure for vancomycin resistance, sources of fever that do not require treatment with vancomycin should be diligently investigated prior to the institution of empiric vancomycin therapy in febrile patients, particularly when the past medical history is suggestive of an alternative diagnosis.
Effect of glycosylphosphatidylinositol (GPI)-phospholipase D overexpression on GPI metabolism
Mann, Karl, Hepworth, Matthew R. , Raikwar, Nandita S., Deeg, Mark A. , Sevlever, Daniel

Mayo Clinic

Biochemical Journal | February 24, 2004 | Volume: 378 | Issue: 2 | Pages: 641-648

10.1042/bj20031326 | PMID 14611645 Get It

GPI-PLD [glycosylphosphatidylinositol (GPI)-specific phospholipase D (PLD)] is a secreted mammalian enzyme that specifically cleaves GPI-anchored proteins. In addition, the enzyme has been shown to cleave GPI anchor intermediates in cell lysates. The biosynthesis of the GPI anchor is well characterized; however, the mechanisms by which the levels of GPI anchor intermediates are regulated are still unknown. To investigate whether GPI-PLD plays a role in this regulation, we isolated stable HeLa cells overexpressing the enzyme. GPI-PLD-HeLa (GPI-PLD-transfected HeLa) cells showed a 3-fold increase in intracellular GPI-PLD activity and drastically decreased the levels of GPI-anchored proteins when compared with untransfected HeLa controls. Intracellular cleavage of GPI-anchored proteins has been suggested to occur early in the secretory pathway and, in agreement with this proposal, GPI-PLD activity in GPI-PLD-HeLa cells was detected not only in the endoplasmic reticulum and Golgi apparatus, but also in the plasma membrane. The enzyme was also active in lipid rafts, membrane microdomains in which GPI-anchored proteins and GPI anchor intermediates are concentrated, indicating that intracellular GPI-PLD cleavage may also occur in this compartment. Pulse–chase paradigms revealed the turnover rate of the last intermediate of the GPI anchor pathway in GPI-PLD-HeLa cells to be accelerated compared with the controls. Furthermore, 1,10-phenanthroline, a GPI-PLD inhibitor, reversed this effect. Our studies demonstrated that GPI-PLD can cleave not only GPI-anchored proteins, but also GPI anchor intermediates intracellularly. This observation opens the possibility that GPI-PLD can influence the steady-state levels of GPI-anchored proteins by hydrolysing the anchor before and after its attachment to proteins.
Improved Specificity of Newborn Screening for Congenital Adrenal Hyperplasia by Second-Tier Steroid Profiling Using Tandem Mass Spectrometry
Lacey, Jean M., Minutti, Carla , Magera, Mark J , Tauscher, Angela L., Casetta, Bruno , McCann, Mark, Lymp, James, Hahn, Si Houn , Rinaldo, Piero, Matern, Dietrich

Mayo Clinic

Clinical Chemistry | February 23, 2004 | Volume: 50 | Issue: 3 | Pages: 621-625

10.1373/clinchem.2003.027193 | PMID 14656905 Get It

Abstract Background: Newborn screening for congenital adrenal hyperplasia (CAH) involves measurement of 17α-hydroxyprogesterone (17-OHP), usually by immunoassay. Because this testing has been characterized by high false-positive rates, we developed a steroid profiling method that uses liquid chromatography–tandem mass spectrometry (LC-MS/MS) to measure 17-OHP, androstenedione, and cortisol simultaneously in blood spots. Methods: Whole blood was eluted from a 4.8-mm (3/16-inch) dried-blood spot by an aqueous solution containing the deuterium-labeled internal standard d8-17-OHP. 17-OHP, androstenedione, and cortisol were extracted into diethyl ether, which was subsequently evaporated and the residue dissolved in LC mobile phase. This extract was injected into a LC-MS/MS equipped with pneumatically assisted electrospray. The steroids were quantified in the selected-reaction monitoring mode by use of peak areas in reference to the stable-isotope-labeled internal standard. We analyzed 857 newborn blood spots, including 14 blood spots of confirmed CAH cases and 101 of false-positive cases by conventional screening. Results: Intra- and interassay CVs for 17-OHP were 7.2–20% and 3.9–18%, respectively, at concentrations of 2, 30, and 50 μg/L. At a cutoff for 17-OHP of 12.5 μg/L and a cutoff of 3.75 for the sum of peak areas for 17-OHP and androstenedione divided by the peak area for cortisol, 86 of the 101 false-positive samples were within reference values by LC-MS/MS, whereas the 742 normal and 14 true-positive results obtained by conventional screening were correctly classified. Conclusion: Steroid profiling in blood spots can identify false-positive results obtained by conventional newborn screening for CAH.
Liquid Chromatography–Tandem Mass Spectrometry Method for the Determination of Vanillylmandelic Acid in Urine
Magera, Mark J , Thompson, Abby L, Matern, Dietrich , Rinaldo, Piero

Mayo Clinic

Clinical Chemistry | February 13, 2004 | Volume: 49 | Issue: 5 | Pages: 825-826

10.1373/49.5.825 | PMID 12709381 Get It

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Therneau, Terry M. , Plevak, Matthew F., Rajkumar, S. Vincent , Fonseca, Rafaël , Greipp, Philip R., Lust, John A., Zeldenrust, Steven R., Snow, Denise S., Hayman, S. R., Litzow, Mark R. , Gastineau, Dennis A., Tefferi, Ayalew , Inwards, David J. , Micallef, Ivana N. , Ansell, Stephen M. , Porrata, Luis F. , Elliott, Michelle A. , Larson, Dirk R. , Witzig, Thomas E. , Gertz, Morie A. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Blood | January 27, 2004 | Volume: 103 | Issue: 10 | Pages: 3960-3963

10.1182/blood-2003-12-4192 | PMID 14739213 Get It

AbstractPrimary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation. Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to sex (57% males), age (median, 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL [97.24 μmol/L]), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups, respectively, the 1-, 2-, and 4-year overall survival rates are 89% and 71%; 81% and 55%; and 71% and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL.
Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study
Callstrom, Matthew R. , Charboneau, J. William, Farrell, Michael A., Maus, Timothy P. , Wong, Gilbert Y., Sloan, Jeff A. , Novotny, Paul J. , Petersen, Ivy A. , Beres, Robert A., Regge, Daniele , Capanna, Rodolfo , Saker, Mark B., Grönemeyer, Dietrich , Gevargez, A., Ahrar, Kamran , Choti, Michael A., Baere, Thierry J. de, Rubin, Joseph, Goetz, Matthew P. , Welch, Timothy J.

Mayo Clinic

Journal of Clinical Oncology | January 13, 2004 | Volume: 22 | Issue: 2 | Pages: 300-306

10.1200/jco.2004.03.097 | PMID 14722039 Get It

Purpose Few options are available for pain relief in patients with bone metastases who fail standard treatments. We sought to determine the benefit of radiofrequency ablation (RFA) in providing pain relief for patients with refractory pain secondary to metastases involving bone. Patients and Methods Thirty-one US and 12 European patients with painful osteolytic metastases involving bone were treated with image-guided RFA using a multitip needle. Treated patients had ≥ 4/10 pain and had either failed or were poor candidates for standard treatments such as radiation or opioid analgesics. Using the Brief Pain Inventory–Short Form, worst pain intensity was the primary end point, with a 2-unit drop considered clinically significant. Results Forty-three patients were treated (median follow-up, 16 weeks). Before RFA, the mean score for worst pain was 7.9 (range, 4/10 to 10/10). Four, 12, and 24 weeks following treatment, worst pain decreased to 4.5 (P < .0001), 3.0 (P < .0001), and 1.4 (P = .0005), respectively. Ninety-five percent (41 of 43 patients) experienced a decrease in pain that was considered clinically significant. Opioid usage significantly decreased at weeks 8 and 12. Adverse events were seen in 3 patients and included (1) a second-degree skin burn at the grounding pad site, (2) transient bowel and bladder incontinence following treatment of a metastasis involving the sacrum, and (3) a fracture of the acetabulum following RFA of an acetabular lesion. Conclusion RFA of painful osteolytic metastases provides significant pain relief for cancer patients who have failed standard treatments.